Journal Mobile Options
Table of Contents
Vol. 46, No. 2, 2011
Issue release date: February 2011

Fournier’s Gangrene: Series of Twenty Patients

Simsek Celik A. · Erdem H. · Guzey D. · Celebi F. · Birol S. · Erozgen F. · Kaplan R.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background and Purpose: Fournier’s gangrene (FG) is a rare, rapidly progressive, fulminant form of necrotizing fasciitis of the genital, perianal and perineal regions. Our aim is to investigate the clinical signs, symptoms and factors which affect the clinical results of patients with FG in our clinic. Patients and Methods: 20 patients having FG were admitted to our department during the past 6-year period. Age, gender, diabetes mellitus (DM), duration of symptoms, FG severity index score (FGSIS), colostomy, hospitalization time and number of debridements were investigated for their effects. Results: 13 of our patients were male, 7 of them were female. The mean age was 52.2 years (range: 30–80 years). 85% of our patients had DM as a predisposing factor. The mean hospitalization time was 19.7 days (range: 6–45 days), and overall mortality was 20% (4 patients). Age and FGSIS have been found to be statistically significant factors among the parameters studied. Discussion: FG is still an important disease with high mortality rates in spite of the developments in intensive care units and new-generation antibiotics. In conclusion, we have found that the age and FGSIS of the patient are the most important effecting factors.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Sahin H, Aflay U, Kilinç N, Bircan MK: Coagulation parameters in the patients with Fournier’s gangrene. Int Urol Nephrol 2005;37:733–737.
  2. Levenson RB, Singh AK, Novelline RA: Fournier gangrene: role of imaging. Radiographics 2008;28:519–528.
  3. Başoğlu M, Gül O, Yildirgan I, Balik AA, Ozbey I, Oren D: Fournier’s gangrene: review of fifteen cases. Am Surg 1997;63:1019–1021.

    External Resources

  4. Kuo CF, Wang WS, Lee CM, Liu CP, Tseng HK: Fournier’s gangrene: ten-year experience in a medical center in northern Taiwan. J Microbiol Immunol Infect 2007;40:500–506.

    External Resources

  5. Murakami M, Okamura K, Hayashi M, Minoh S, Morishige I, Hamano K: Fournier’s gangrene treated by simultaneously using colostomy and open drainage. J Infect 2006;53:e15–e18.
  6. Basoglu M, Ozbey I, Atamanalp SS, Yildirgan MI, Aydinli B, Polat O, et al: Management of Fournier’s gangrene: review of 45 cases. Surg Today 2007;37:558–563.
  7. Yanar H, Taviloglu K, Ertekin C, Guloglu R, Zorba U, Cabioglu N, et al: Fournier’s gangrene: risk factors and strategies for management. World J Surg 2006;30:1750–1754.
  8. Taviloglu K, Gunay K, Ertekin C, Gencosmanoglu R, Turel O: Necrotizing fasciitis: therapeutical modalities (in Turkish). Turk J Sur 1996;12:128–133.
  9. Sørensen MD, Krieger JN, Frederick PR, Broghammer JA, Klein MB, Mack CD, et al: Fournier’s gangrene: population based epidemiology and outcomes. J Urol 2009;181:2120–2126.
  10. Corcoran AT, Smaldone MC, Gibbons EP, Walsh TJ, Davies BJ: Validation of the Fournier’s gangrene severity index in a large contemporary series. J Urol 2008;180:944–948.
  11. Unalp HR, Kamer E, Derici H, Atahan K, Balci U, Demirdoven C, et al: Fournier’s gangrene: evaluation of 68 patients and analysis of prognostic variables. J Postgrad Med 2008;54:102–105.
  12. Corman JM, Moody JA, Aronson WJ: Fournier’s gangrene in a modern surgical setting: improved survival with aggressive management. BJU Int 1999;84:85–88.
  13. Tahmaz L, Erdemir F, Kibar Y, Cosar A, Yalcin O: Fournier’s gangrene: report of thirty-three cases and a review of the literature. Int J Urol 2006;13:960–967.
  14. Jeong HJ, Park SC, Seo IY, Rim JS: Prognostic factors in Fournier gangrene. Int J Urol 2005;12:1041–1044.
  15. Vick R, Carson CC: Fournier’s disease. Urol Clin North Am 1999;26:841–849.
  16. Eke N: Fournier’s gangrene: a review of 1,726 cases. Br J Surgery 2000;87:718–728.
  17. Clayton MD, Fowler JE, Sharifi R, Pearl RK: Causes, presentation and survival of fifty-seven patients with necrotizing fasciitis of the male genitalia. Surg Gynecol Obstet 1990;170:49–55.
  18. Laor E, Palmer LS, Tolia BM, Reid RE, Winter HI: Outcome prediction in patients with Fournier’s gangrene. J Urol 1995;154:89–92.
  19. Sørensen MD, Krieger JN, Rivara FP, Klein MB, Wessells H: Fournier’s Gangrene: management and mortality predictors in a population based study. J Urol 2009;182:2742–2747.
  20. Yeniyol CO, Suelozgen T, Arslan M, Ayder AR: Fournier’s gangrene: experience with 25 patients and use of Fournier’s gangrene severity index score. Urology 2004;64:218–222.
  21. Benizri E, Fabiani P, Migliori G, Chevallier D, Peyrottes A, Raucoules M, et al: Gangrene of the perineum. Urology 1996;47:935–939.
  22. Chawla SN, Gallop C, Mydlo JH: Fournier’s gangrene: an analysis of repeated surgical debridement. Eur Urol 2003;43:572–575.
  23. Kabay S, Yucel M, Yaylak F, Algin MC, Hacioglu A, Kabay B, et al: The clinical features of Fournier’s gangrene and the predictivity of the Fournier’s gangrene severity index on the outcomes. Int Urol Nephrol 2008;40:997–1004.
  24. Laucks SS: Fournier’s gangrene. Surg Clin North Am 1994;74:1339–1352.
  25. Faucher LD, Morris SE, Edelman LS, Saffle JR: Burn center management of necrotizing soft-tissue surgical infections in unburned patients. Am J Surg 2001;182:563–569.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50